Business
New Major Pharmaceutical Client
New Major Pharmaceutical Client.
About this update from Physiomics Plc
[{"type":"text","content":"\n \nRNS Number : 9521C Physiomics PLC 26 January 2018 \n\n26th January 2018\nPhysiomics plc \n(\"Physiomics\") or (\"the Company\")\n \nNew Major Pharmaceutical Client\n \nPhysiomics plc (AIM: PYC), a provider of technology-based solutions to predict the effects of cancer treatment regimens for the biopharma industry, is pleased to announce that it has been awarded a contract by a new major pharmaceutical client. The project, which is expected to be completed during the Company's current financial year involves the use of Physiomics' Virtual Tumour technology in a pre-clinical setting and its value is approximately £35k.\n \nPhysiomics' Virtual Tumour is a sophisticated computer model that simulates tumour cell division and predicts the effect of different anti-cancer regimes to support pre-clinical and clinical oncology development programs. Virtual Tumour helps customers to balance efficacy and toxicity and to prioritise the most effective drug combinations while reducing time and cost.\n \nJim Millen, CEO said: \"We are delighted to be working with a significant new client. If this initial project is successful, we would hope to develop a longer-term relationship.\"\n \n \nEnquiries:\n \nPhysiomics plc \nDr Jim Millen, CEO\n+44 (0)1865 784 980\n \nWH Ireland Limited (nomad)\nKaty Mitchell\n+44 (0) 161 832 2174\n \nHybridan LLP (broker)\nClaire Louise Noyce\n+44 (0) 203 764 2341\n \nNotes to Editor\n \nAbout Physiomics\n \nPhysiomics plc (AIM: PYC) is a solutions provider to the R&D based pharmaceutical and biotechnology industry with a focus on oncology. The Company's Virtual Tumour technology uses computer modelling to predict the effects of cancer drugs and treatments to improve the success rate of drug discovery and development projects while reducing time and cost. The predictive capability of Virtual Tumour has been confirmed by 55 projects, involving over 25 targets and 60 drugs, and has worked with clients such as Merck KGaA, Merck & Co, Ba...